Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.

Stelmachowska-Banas, Maria; Czajka-Oraniec, Izabella; Tomasik, Agnieszka; Zgliczynski, Wojciech

Stelmachowska-Banas, Maria; Czajka-Oraniec, Izabella; Tomasik, Agnieszka; Zgliczynski, Wojciech.

Afiliação

Stelmachowska-Banas M; Department of Endocrinology, The Centre of Postgraduate Medical Education, Warsaw, Poland. mstelmachowska@cmkp.edu.pl.
Czajka-Oraniec I; Department of Endocrinology, The Centre of Postgraduate Medical Education, Warsaw, Poland.
Tomasik A; Department of Endocrinology, The Centre of Postgraduate Medical Education, Warsaw, Poland.
Zgliczynski W; Department of Endocrinology, The Centre of Postgraduate Medical Education, Warsaw, Poland.

Pituitary ; 25(1): 180-190, 2022 Feb.

Article em En | MEDLINE | ID: mdl-34498217

Assuntos

Acromegalia; Somatostatina; Acromegalia/tratamento farmacológico; Hormônio do Crescimento Humano; Humanos; Fator de Crescimento Insulin-Like I; Octreotida; Estudos Prospectivos; Somatostatina/efeitos adversos; Somatostatina/análogos & derivados; Resultado do Tratamento

Palavras-chave

Acromegaly; Diabetes mellitus; Growth hormone; Insulin-like growth factor-1; Pasireotide-LAR

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acromegalia / Somatostatina Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Polônia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google